IRCT20200105046010N103招募中Unknown
In-vivo Bioequivalence Study of Ranolazine 500 mg extended-release tablets (Arang Pharma, Iran) With Brand Drug (RANEXA® 500 mg ER. tablets, Menarini Pharma, Luxemburg) in Iranian Healthy
Arang Pharm Co.0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28) kg/m^2
- •Informed consent
- •Informed consentAge (18-55 years old)
排除标准
- •Nicotine consumption
- •historyCardiovascular disease
- •disease HistoryLiver and kidney disease
- •HistoryAlcohol and opioid addiction
- •Allergy reactions history to Linagliptin or Metformin
研究者
相似试验
招募中
Unknown
Comparative in vivo evaluation of 2 Ranolazine 1000 mg ER Tablet and Ranexa® 1000 mg ER Tablet formulations.Angina pectoris.Angina pectorisIRCT20180620040164N50Zist Arvand Pharme Ltd.24
招募中
2 期
Evaluation of the effect of Ranolazine on patients with slow flow coronary arteriesIRCT20220516054874N6Mashhad University of Medical Sciences48
招募中
Unknown
Comparative in vivo evaluation of 2 Mesalazine 500 mg ER Capsule and Mesalazine 500 mg ER Tablet formulations.Ulcerative colitisIRCT20180620040164N46Karen Pharma and Food Supplement Co.24
已完成
Unknown
Comparative in vivo evaluation of 2 Mesalazine 500 mg ER Capsule and PENTASA® 500 mg ER Tablet formulations.Ulcerative colitisIRCT20180620040164N49Actover Pharmaceutical Co.24
尚未招募
不适用
Efficacy of Ranolazine in treating ventricular premature beatspremature ventricular beats, ventricular premature depolarization, premature ventricular complexes, premature ventricular contraction.Ventricular premature depolarizationI49.3IRCT20220515054863N2Tehran University of Medical Sciences96